360 related articles for article (PubMed ID: 19057798)
1. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
2. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
3. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
4. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
6. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy and thyrostatic drugs and iodine.
Moka D; Dietlein M; Schicha H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
[TBL] [Abstract][Full Text] [Related]
8. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
9. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
[TBL] [Abstract][Full Text] [Related]
10. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
12. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
13. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
Róka R; Séra T; Valkusz Z; Julesz J; Csernay L; Pávics L
Orv Hetil; 1999 Jun; 140(23):1291-5. PubMed ID: 10412264
[TBL] [Abstract][Full Text] [Related]
14. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
15. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
16. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
Baczyk M; Junik R; Ziemnicka K; Sowiński J
Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
[TBL] [Abstract][Full Text] [Related]
17. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
Guhlmann CA; Rendl J; Börner W
Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
[TBL] [Abstract][Full Text] [Related]
18. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
Traino AC; Grosso M; Mariani G
Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
[TBL] [Abstract][Full Text] [Related]
19. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of diffuse hyperthyroid goiter with radioiodine: influence of propylthiouracil pretreatment].
Véliz J; Pineda G; Arancibia P; Wohllk N
Rev Med Chil; 2000 Jun; 128(6):609-12. PubMed ID: 11016059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
